Englerins: A Comprehensive Review.
In the decade since the discovery of englerin A (1) and its potent activity in cancer models, this natural product and its analogues have been the subject of numerous chemical, biological, and preclinical studies by many research groups. This review summarizes published findings and proposes further research directions required for entry of an englerin analogue into clinical trials for kidney cancer and other conditions.
Department of Chemistry and Biochemistry, University of Delaware , Newark, Delaware 19716, United States.
Zhenhua
Z
Wu
Department of Chemistry and Biochemistry, University of Delaware , Newark, Delaware 19716, United States.
Senzhi
S
Zhao
Department of Chemistry and Biochemistry, University of Delaware , Newark, Delaware 19716, United States.
David M
DM
Fash
Department of Chemistry and Biochemistry, University of Delaware , Newark, Delaware 19716, United States.
Zhenwu
Z
Li
Department of Chemistry and Biochemistry, University of Delaware , Newark, Delaware 19716, United States.
William J
WJ
Chain
Molecular Targets Laboratory, Center for Cancer Research, National Cancer Institute , Frederick, Maryland 21702, United States.
John A
0000-0002-4646-1924
JA
Beutler
D000972:Antineoplastic Agents, Phytogenic; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D015394:Molecular Structure; D045789:Sesquiterpenes, Guaiane
D000972:Antineoplastic Agents, Phytogenic; D045789:Sesquiterpenes, Guaiane; C534971:englerin A